Bio Pharma Dive
JANUARY 3, 2023
By the end of June, highly anticipated study results are expected in Alzheimer’s, obesity and Huntington’s disease, while a pair of high-priced acquisitions could be put to the test
Pharmaceutical Technology
JANUARY 6, 2023
While the treatment options for multiple sclerosis (MS) patients are growing each year with the approval of new agents, all of the currently marketed treatments only slow the disease’s progression and sometimes carry risks of severe side effects, such as liver failure or the development of viral infections.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharma Mirror
JANUARY 1, 2023
by Dr Torill Bigg, Chief Carbon Reduction Engineer at Tunley Engineering Businesses globally are looking to reduce their carbon footprints. A number of factors is driving this activity. It is a smart and ethical business practice to operate sustainably for the environment and for grand success.
The Pharma Data
JANUARY 5, 2023
Research led by Associate Professor Duc Dong, Ph.D., has shown for the first time that the effects of Alagille syndrome, an incurable genetic disorder that affects the liver, could be reversed with a single drug.
Advertiser: FourKites
Download this a benchmark study from FourKites and The Journal of Commerce exploring how international shippers’ usage of global supply chain visibility technology has evolved since the onset of global disruptions caused by COVID-19.
Bio Pharma Dive
JANUARY 6, 2023
The agency’s approval comes months after a large clinical trial showed the drug, called Leqembi, could slow the disease’s progression. Yet experts have raised concerns about its safety
Pharmaceutical Technology
JANUARY 6, 2023
Last week, Novartis announced plans to pay $245 million to end a pay-for-delay legal battle that started in 2018. This settlement ends a packed year of legal rulings for the Swiss pharmaceutical giant.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
The Pharma Data
JANUARY 5, 2023
Biogen Inc. Nasdaq: BIIB) announced that Priya Singhal, M.D., M.P.H.,
Bio Pharma Dive
JANUARY 6, 2023
The pharma set the average annual cost of it and Biogen’s newly approved medicine Leqembi to $26,500, below the cost of the companies’ earlier drug Aduhelm but above one estimate of cost effectiveness
Pharmaceutical Technology
JANUARY 4, 2023
The China National Medical Products Administration’s (NMPA) Center for Drug Evaluation (CDE) has granted clearance for Transcenta’s investigational new drug (IND) application for its TST003 to treat solid tumours. TST003 is a first-in-class Gremlin1 targeting humanised monoclonal antibody.
Pharma Phorum
JANUARY 6, 2023
Google and DeepMind have developed an artificial intelligence-powered chatbot tool called Med-PaLM designed to generate “safe and helpful answers” to questions posed by healthcare professionals and patients.
Speaker: Steve Goldstein, Sales Leader
Currently in sales or involved in a business that depends on strong sales results? Join Steve Goldstein, Sales Success Coach, Motivational Speaker and Medical Device Sales Leader from Gold Selling LLC. You will absorb critical strategies to become a trusted partner in greater sales success.
The Pharma Data
JANUARY 5, 2023
FDA accepts nirsevimab application as first protective option against RSV disease for all infants. Nirsevimab would be the first broadly protective option against RSV disease designed for all infants, if approved.
Bio Pharma Dive
JANUARY 4, 2023
The Lilly-owned subsidiary will pay $55 million to gain access to Capsida’s AAV gene therapy technology in a deal aimed at central nervous system disorders
Pharmaceutical Technology
JANUARY 5, 2023
Capsida Biotherapeutics and Eli Lilly and Company ’s wholly owned subsidiary Prevail Therapeutics have announced a partnership for the development of non-invasive gene therapies for central nervous system (CNS) diseases.
Pharma Times
JANUARY 3, 2023
Company has reported booster details from a study of its inactivated COVID-19 candidate
Advertiser: Aggregage
The federal government is developing a rule requiring employers with more than 100 employees ensure their workers are vaccinated or produce a negative COVID test weekly before entering the workplace. So, what can your organization do to prepare? Get Paycor’s COVID Vaccination Policy Template to help communicate important details to your employees.
The Pharma Data
JANUARY 4, 2023
Gilead Receives Rights to Exclusively License EVOQ’s NanoDisc Technology to Develop and Commercialize Immunotherapy Products for Rheumatoid Arthritis and Lupus –. Gilead Sciences, Inc. Nasdaq: GILD) and EVOQ Therapeutics , Inc.
Bio Pharma Dive
JANUARY 6, 2023
The Takeda-backed biotech revealed it’s raised $85 million in new funding alongside announcing the acquisition of gene editing startup Twelve Bio
Pharmaceutical Technology
JANUARY 5, 2023
The swift development of COVID-19 vaccines was an unprecedented scientific and collaborative achievement by government, regulators, research institutions, and the pharmaceutical industry.
Pharma Times
JANUARY 6, 2023
Study will evaluate the intravenous administration of company’s multi-armed immunotherapy
Fierce Pharma
JANUARY 4, 2023
Pfizer, GSK, AbbVie and many more celebrate New Year with price hikes: report. esagonowsky. Wed, 01/04/2023 - 10:21
Bio Pharma Dive
JANUARY 6, 2023
The cuts at Fate, Century Therapeutics and TCR2 Therapeutics signal a longer road in the companies’ plans to develop next-generation cell therapies for cancer
Pharmaceutical Technology
JANUARY 6, 2023
The US Food and Drug Administration (FDA) has accepted AstraZeneca ’s nirsevimab biologics licence application (BLA) for review to prevent respiratory syncytial virus (RSV) lower respiratory tract disease in children aged up to 24 months.
Pharma Times
JANUARY 5, 2023
Agreement covers cell-based studies, with an additional option to further develop screening activities
BioPharma Reporter
JANUARY 2, 2023
Last week saw Opus Genetics announce it had acquired the rights to two preclinical-stage adeno-associated virus (AAV)-based gene therapy product candidates for inherited retinal diseases (IRDs) from Iveric Bio. Markets & Regulations
Bio Pharma Dive
JANUARY 6, 2023
The gene therapy developer will receive $95 million from Bristol Myers Squibb, slightly less than it got in the recent sale of another priority review voucher
Pharmaceutical Technology
JANUARY 6, 2023
Danish biotech company Adcendo has entered into a licence agreement with Duality Biologics on the next-generation antibody-drug conjugates (ADC) platform.
Pharma Times
JANUARY 4, 2023
European Medicines Agency will consider therapy for the treatment of patients with multiple myeloma
Fierce Pharma
JANUARY 3, 2023
COVID-19 tracker: AstraZeneca workers who were fired for refusing vaccine file lawsuit. kdunleavy. Tue, 01/03/2023 - 10:31
Bio Pharma Dive
JANUARY 3, 2023
Analysts noted hundreds of wholesale price increases, including dozens by Pfizer. Many checked in around 5%, roughly in line with hikes taken in recent years
Pharmaceutical Technology
JANUARY 6, 2023
Dutch biotechnology company Synaffix and Amgen have entered a licensing agreement for the development of next-generation antibody-drug conjugates (ADCs).
Pharma Times
JANUARY 3, 2023
Second study will develop a bispecific antibody with potential applications in solid tumours
Pharma Phorum
JANUARY 6, 2023
The UK has formed an partnership with German biotech BioNTech to provide up to 10,000 patients with access to personalised cancer therapies, in another example of the country embracing the mRNA technologies that underpinned COVID-19 vaccines.
Bio Pharma Dive
JANUARY 4, 2023
The Versant-backed company emerged from stealth with technology it says can help it better identify small molecule drugs for any target on any protein
Pharmaceutical Technology
JANUARY 6, 2023
Formulating products that have the proper composition, viscosity, texture, and stability, and can also be shown to be safe and effective, is both a science and an art.
Pharma Times
JANUARY 5, 2023
Safety, tolerability and pharmacokinetic endpoints for MTX652 have been successfully met
Expert insights. Personalized for you.
272 
Let's personalize your content